Alzheimer’s Disease Study

Alzheimer’s is a devastating type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly in the sixth to eighth decade, and get worse over time, becoming severe enough to interfere with daily tasks. As our population ages, effective treatments to slow down and even reverse Alzheimer’s are desperately needed.  At New England Institute for Clinical Research, we currently are working on just that.  Our studies in this disease state include:

 

  • A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease Learn More
  • A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ) Learn More
  • A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease_ (MissionAD2) Learn More
  • A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer’s Disease Learn More
  • A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease(Generation S1) Learn More

    *As Featured in the News*

Use the form below to enroll

Clinical Study Enrollment - Alzheimer’s Disease
First
Last
Sending